SMARCA4 and neoplasm: By IHC, the tumor demonstrated diffuse positivity to synaptophysin, PLAP negativity, retained INI-1, focally retained ATRX expression, and focally retained nuclear expression of SMARCA4 (Fig. 4e and i).